| abstract |
The present invention relates to a composition for the prevention or treatment of diabetes, diabetic complications or diabesity, comprising an oxyntomodulin analogue as an active ingredient. The invention also relates to a method of treating diabetes, diabetic complications or diabesity, comprising administering a pharmaceutically effective amount of an oxyntomodulin analogue to a patient. The oxyntomodulin analogue has a high ability to activate the GLP-1 receptor and the glucagon receptor compared to native oxyntomodulin. The oxyntomodulin analogue induces beta cell expansion and increases insulin secretion, thereby reducing blood glucose levels that were raised due to a high-calorie, high-fat diet. The oxyntomodulin analogue induces a decrease in body weight and dietary intake to increase insulin sensitivity and allow blood glucose levels, which are not controlled due to insulin resistance, to be maintained at normal levels. Thus, the oxyntomodulin analogue can be effectively used to prevent or treat diabetes and related diseases. |